Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...
Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...
Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic ...
As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding groundbreaking projects, has awarded the University of Houston $3 million to set up a ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
This collection examines the critical role of biomarkers in clinical trials in breast cancer and their impact on personalized medicine. It covers predictive and prognostic biomarkers that guide ...
Eight research projects are already underway, including efforts to predict treatment response, identify novel biomarkers and analyze rare cancer trends. Collectively, the participating centers bring ...
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named a Top 5 “Best ...
BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback